Ivabradin Puren (Ivabradine)

Ivabradine selectively blocks the funny (If) current in the sinoatrial node, the primary pacemaker of the heart. Inhibition of this current slows the spontaneous depolarisation of pacemaker cells, leading to a reduction in heart rate without affecting myocardial contractility or blood pressure.

The dose of Ivabradin Puren is determined individually by a qualified prescriber based on the patient’s clinical condition, heart‑rate response, and tolerance. Physicians adjust the regimen according to therapeutic goals and safety monitoring, and patients should follow the prescribed instructions exactly.

Safety data for ivabradine in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used when the potential benefit justifies the potential risk to the fetus or infant, and a healthcare professional must evaluate each case.

To place an order, submit an enquiry on the Ivabradin Puren product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

The primary alternative for heart‑rate reduction in angina and heart failure is beta‑blockers. Unlike beta‑blockers, ivabradine lowers heart rate without influencing beta‑adrenergic receptors, so it does not affect blood pressure or contractility and can be added when beta‑blockers are insufficient or not tolerated.

Store Ivabradin Puren tablets at room temperature, below 25 °C, in the original packaging. Keep the container tightly closed, protect it from moisture and direct sunlight, and keep it out of reach of children. Do not refrigerate or freeze the product.

Ivabradin Puren is taken orally as a whole tablet with a glass of water. It may be taken with or without food, but the dose should be swallowed whole and not split, crushed, or chewed unless otherwise directed by a healthcare professional.

Serious adverse events include symptomatic bradycardia, atrial fibrillation, and severe visual disturbances such as persistent phosphenes. Patients should report any unusually slow heart rate, palpitations, fainting, or new visual symptoms to their prescriber promptly.

Ivabradin Puren is contraindicated in patients with acute decompensated heart failure, severe hypotension, sick sinus syndrome, or a resting heart rate below 60 bpm. It should also be avoided in individuals with known hypersensitivity to ivabradine or any of the tablet’s excipients.